Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma

ACTIVITY DESCRIPTION
Patients with multiple myeloma that is refractory to multiple classes of therapeutics can be particularly difficult to treat. Fortunately, the treatment landscape is expanding, and a range of new therapies for patients with multiply relapsed or refractory multiple myeloma (RRMM) is rapidly emerging. In particular, chimeric antigen receptor (CAR) T-cell therapy is a powerful new immunotherapy that has revolutionized cancer treatment and has been approved for patients with RRMM. However, the CAR T process is long and complex, with challenges associated with each phase of the process and unique adverse events. Also on the horizon are bispecific antibodies, another type of T cell"activating therapy that offers an off-the-shelf option that may be ideal for patients that need to initiate treatment quickly.

This webcast features evidence-based presentations along with patient cases designed to address the nuances of T cell"activating therapy use, identification of patients that are the best candidates for these approaches, and options for patients who may not be candidates for this therapy.

Educational Objectives
Upon completion of the educational activity, participants should be able to: 1) Evaluate recent clinical advances in the use of T cell"activating therapies in patients with RRMM and their implications for clinical practice; 2) Summarize the toxicity profiles of T cell"activating therapies used in the treatment of RRMM, particularly with respect to cytokine release syndrome (CRS), infections, and immune effector cell"associated neurotoxicity syndrome (ICANS); 3) Describe the unique aspects of manufacturing, bridging therapy, and the need for lymphodepletion associated with CAR T-cell therapies used to treat RRMM